Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)

Muhammad Arif; Aart Jan Lelij; Patric Delhanty; Alof Dallenga; Iain Haitsma; J.A.M.J.L. Janssen; S.J.C.M.M. Neggers

doi:10.1210/jc.2017-02017

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)

Muhammad Arif, Aart Jan Lelij, Patric Delhanty, Alof Dallenga, Iain Haitsma, J.A.M.J.L. Janssen, S.J.C.M.M. Neggers

Research output: Contribution to journal › Article › Academic › peer-review

65 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	586-595
Number of pages	10
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	103
Issue number	2
DOIs	https://doi.org/10.1210/jc.2017-02017
Publication status	Published - 2018

Research programs

EMC MM-01-39-01
EMC MM-01-39-04

Access to Document

10.1210/jc.2017-02017

http://hdl.handle.net/1765/112840

Cite this

Arif, M., Lelij, A. J., Delhanty, P., Dallenga, A., Haitsma, I., Janssen, J. A. M. J. L., & Neggers, S. J. C. M. M. (2018). Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). Journal of Clinical Endocrinology and Metabolism, 103(2), 586-595. https://doi.org/10.1210/jc.2017-02017

@article{2d02e052106e44e790fea6e29a32ed23,

title = "Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)",

author = "Muhammad Arif and Lelij, {Aart Jan} and Patric Delhanty and Alof Dallenga and Iain Haitsma and J.A.M.J.L. Janssen and S.J.C.M.M. Neggers",

year = "2018",

doi = "10.1210/jc.2017-02017",

language = "Undefined/Unknown",

volume = "103",

pages = "586--595",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "2",

}

Arif, M , Lelij, AJ , Delhanty, P, Dallenga, A, Haitsma, I , Janssen, JAMJL & Neggers, SJCMM 2018, 'Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 2, pp. 586-595. https://doi.org/10.1210/jc.2017-02017

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). / Arif, Muhammad ; Lelij, Aart Jan ; Delhanty, Patric et al.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 2, 2018, p. 586-595.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)

AU - Arif, Muhammad

AU - Lelij, Aart Jan

AU - Delhanty, Patric

AU - Dallenga, Alof

AU - Haitsma, Iain

AU - Janssen, J.A.M.J.L.

AU - Neggers, S.J.C.M.M.

PY - 2018

Y1 - 2018

U2 - 10.1210/jc.2017-02017

DO - 10.1210/jc.2017-02017

M3 - Article

C2 - 29155991

SN - 0021-972X

VL - 103

SP - 586

EP - 595

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 2

ER -